Thank you for registering with Pulmonary Fibrosis New’s Clinical Trial Registry.
We will inform you of new clinical trials as information becomes available.
In the meantime, feel free to access these other PF-related resources:
Ofev News:
- Switching Between Antifibrotics May Help IPF Patients Live Longer
- Ofev Effective in Elderly Patients, Those With Comorbidities
- SAN903, for IPF, Significantly Lessens Fibrosis in Animal Study
- MUC5B Mutation May Lengthen Life for IPF Patients on Anti-fibrotics
- Ofev May Help Treat IPF With Lung Cancer, Case Report Suggests
- Esbriet, Ofev Found to Benefit IPF Patients in Clinical Practice
- KL-6 Protein Found to Be a Promising Biomarker for IPF Prognosis
IPF News:
- Lungs ‘Primed’ for Severe COVID-19 in People With IPF-like Disorders
- US Patent Awaited for Nuformix’s Potential IPF Inhalation Therapy
- Dosing Begins in 2nd Phase 3 Trial of Antibody Treatment for IPF
- Phase 2 Trial of C21, Potential Oral Therapy for IPF, Opens
- Procalcitonin Blood Levels May Help Detect Lung Cancer in IPF Patients, Study Suggests
- Biognosys, Boehringer Ingelheim Partner for Protein Studies of IPF
- World’s First Single-cell Sequencing Atlas Available for Drug Discovery in IPF
Esbriet News:
- Switching Between Antifibrotics May Help IPF Patients Live Longer
- Esbriet Slows IPF Progression Regardless of Self-reactive Antibodies
- Changes in Blood Cell Ratios Linked to Worse Outcomes
- Compound in Medicinal Herb Shows Anti-fibrotic Potential
- MUC5B Mutation May Lengthen Life for IPF Patients on Anti-fibrotics
- Esbriet, Ofev Found to Benefit IPF Patients in Clinical Practice
- GALACTIC-1 Trial of Inhaled IPF Therapy to Stop High Dose, Restrict Low Dose
CPF News:
- Evel Knievel: Dedicated to Defying Death, Lost To IPF
- PFF Brings Daughters of PF Program Under Its Wings
- CPF Names 2014 Most Important Year for Pulmonary Fibrosis
- FDA Includes CPF Advocates in IPF Workshop
- CPF Organizing a Series of Educational Activities for the 2014 Pulmonary Fibrosis Awareness Month
- PFF and CPF Documentary About Idiopathic Pulmonary Fibrosis to Air on Discovery Channel
- Coalition for Pulmonary Fibrosis Group Leads National Pulmonary Fibrosis Month
IPF Clinical Trial News:
- Ofev Effective in Elderly Patients, Those With Comorbidities
- UK Trial Recruiting IPF Patients to Test Nalbuphine Extended Release Tablets for Chronic Cough
- ART-123 Doesn’t Prolong Life in IPF Acute Exacerbations, Study Says
- 4 Factors that Impact Pulmonary Fibrosis Prevention
- Galecto’s Inhaled TD139 a Promising Therapy for IPF, Scottish Study Finds
- Bellerophon’s INOpulse Inhaled Nitrous Oxide Device Improves Symptoms of PH-IPF Patients, Study Finds
- Kadmon Presents Preclinical Data Supporting ROCK Inhibition as Way of Treating PF
FDA News:
- FDA Accepts Priority Review Request for Tyvaso DPI
- IM156 on Fast Track as IPF Treatment
- United Therapeutics Asks FDA to Approve Tyvaso DPI
- FDA Designates Axatilimab an Orphan Drug for IPF
- FDA Clears Potential IPF Therapy, IM156, for Phase 1 Trial
- FDA Grants Priority Review to Esbriet for Unclassifiable Interstitial Lung Disease
- Treprostinil Earns FDA Orphan Drug Designation for Treating IPF